Drug Trial Radar · NCT06060613
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
254
Planned (sponsor's estimate)
Start
Oct 25, 2023
Primary completion
Jun 30, 2029
Study completion Jun 30, 2029
Sponsor
- Lead sponsor
- Obsidian Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 29, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.
Conditions
- Tumor Skin
- Metastatic Melanoma
- Melanoma
- Lung Cancer
- Metastatic Lung Cancer
- Non Small Cell Lung Cancer
- Metastatic Non Small Cell Lung Cancer
Interventions
OBX-115Biological
A tumor sample is obtained from each participant for autologous OBX-115 manufacture. After lymphodepletion including cyclophosphamide and fludarabine, participant will receive OBX-115 infusion, followed by short courses of acetazolamide.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and nature of dose-limiting toxicities (DLTs)Time frame: 28 Days
- The proportion of participants who have a confirmed complete response (CR) or partial response (PR) per RECIST v1.1Time frame: 2 years
- The proportion of participants who have a confirmed complete response (CR) or partial response (PR) per RECIST v1.1Time frame: 2 years
Locations
14 sites in 2 countries. Site status is shown where the registry gives one.
Banner Health
Tucson, Arizona · Recruiting
The Angeles Clinic and Research Institute (Melanoma)
Los Angeles, California · Recruiting
USC Norris Comprehensive Cancer Center (Melanoma/NSCLC)
Los Angeles, California · Recruiting
Stanford Cancer Institute (Melanoma/NSCLC)
Stanford, California · Recruiting
University of Miami
Miami, Florida · Recruiting
Advent Health Orlando
Orlando, Florida · Recruiting
Orlando Health Cancer Institute (Melanoma/NSCLC)
Orlando, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
James Graham Brown Cancer Center (Melanoma/NSCLC)
Louisville, Kentucky · Recruiting
Memorial Sloan Kettering (Melanoma/NSCLC)
New York, New York · Recruiting
The Ohio State University
Columbus, Ohio · Active not recruiting
Allegheny Research Institute (Melanoma/NSCLC)
Pittsburgh, Pennsylvania · Recruiting
M.D. Anderson Cancer Center (Melanoma/NSCLC)
Houston, Texas · Recruiting
Melanoma Institute of Australia
Wollstonecraft, New South Wales, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.